| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 07/20/2000 | WO2000041994A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/20/2000 | WO2000041694A2 Compositions having improved stability |
| 07/20/2000 | WO2000041693A2 Compositions having improved delivery of actives |
| 07/20/2000 | WO2000041692A2 Compositions having improved stability |
| 07/20/2000 | WO2000041566A1 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/20/2000 | WO2000041505A2 Anthranilic acid derivatives |
| 07/20/2000 | WO2000021510A3 Formulations of fexofenadine |
| 07/20/2000 | WO2000019984A3 Coated medicament forms with controlled active substance release |
| 07/20/2000 | WO2000015246A3 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 07/20/2000 | WO2000014097A3 Novel pyranoses |
| 07/20/2000 | WO2000010598B1 Recombinant botulinium toxin for the treatment of mucus hypersecretion |
| 07/20/2000 | CA2697598A1 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | CA2360386A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2360358A1 Compositions having improved stability |
| 07/20/2000 | CA2359986A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors |
| 07/20/2000 | CA2359980A1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 07/20/2000 | CA2359449A1 Phenanthridine-n-oxides with pde-iv inhibiting activity |
| 07/20/2000 | CA2359416A1 6-arylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2359404A1 Phenanthridine-n-oxides with pde-iv inhibiting activity |
| 07/20/2000 | CA2359067A1 Polypeptide variants with altered effector function |
| 07/20/2000 | CA2356944A1 Compositions having improved stability |
| 07/20/2000 | CA2352509A1 Cinnamamide derivatives and pharmaceutical compositions containing the same |
| 07/20/2000 | CA2349180A1 Anthranilic acid derivatives |
| 07/20/2000 | CA2348236A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/19/2000 | EP1019501A1 Novel pyrimidine derivative |
| 07/19/2000 | EP1019427A1 N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 07/19/2000 | EP1019406A1 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 07/19/2000 | EP1019399A1 Aryl thiophene derivatives as pde iv inhibitors |
| 07/19/2000 | EP1019396A1 Novel cycloalkyl substituted imidazoles |
| 07/19/2000 | EP1019394A1 PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
| 07/19/2000 | EP1019382A1 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| 07/19/2000 | EP1019360A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 07/19/2000 | EP1019075A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 07/19/2000 | EP1019065A1 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications |
| 07/19/2000 | EP1019063A1 Modulation of immune responses |
| 07/19/2000 | EP1019040A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| 07/19/2000 | EP1019033A1 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising budesonide |
| 07/19/2000 | EP1019023A1 Stabilized preparations for use in nebulizers |
| 07/19/2000 | EP1019022A1 Perforated microparticles and methods of use |
| 07/19/2000 | EP1019021A1 Stabilized preparations for use in metered dose inhalers |
| 07/19/2000 | EP1019020A1 Stabilized bioactive preparations and methods of use |
| 07/19/2000 | EP0735877B1 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
| 07/19/2000 | CN1260795A Quaternary ammonium compounds as tachykinin antagenists |
| 07/19/2000 | CN1260784A Quinoline derivatives as PDEIV and INF inhibitors |
| 07/19/2000 | CN1260182A Duanxiaoling (curing asthma) and its preparation method |
| 07/19/2000 | CN1260180A Application of lung surface active matter to pharmaceutical industry |
| 07/19/2000 | CN1054603C Tri-substituted phenyl derivatives and medicinal composition containing same |
| 07/18/2000 | US6090845 Hypotensive agent; vision defects |
| 07/18/2000 | US6090824 Therapeutic neurokinin receptor antagonist compounds |
| 07/18/2000 | US6090817 Respiratory system disorders; phosphodiesterse inhibitor |
| 07/18/2000 | US6090816 Antiasthma agents |
| 07/18/2000 | US6090618 DNA constructs and viral vectors comprising a smooth muscle promoter |
| 07/18/2000 | US6090612 Polynucleotide sequence coding a phosphatase enzymes; a diagnostic tool for monitoring enzyme activity in sample; for treatment of nervous system disorders, cardiovascular disorders and tumors; antitumor agents |
| 07/18/2000 | US6090579 Human SDR2 cDNA clone |
| 07/18/2000 | US6090382 Human antibodies that bind human TNFα |
| 07/18/2000 | CA2008183C Liquid pharmaceutical composition for piperidinoalkanol derivatives |
| 07/13/2000 | WO2000040733A1 Human cyclic nucleotide pdes |
| 07/13/2000 | WO2000040716A2 Soluble receptor br43x2 and methods of using them for therapy |
| 07/13/2000 | WO2000040714A2 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | WO2000040612A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040600A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | WO2000040578A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040548A1 Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| 07/13/2000 | WO2000040539A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
| 07/13/2000 | WO2000040243A1 Novel compounds |
| 07/13/2000 | WO2000040241A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | WO2000040239A1 Compounds and methods |
| 07/13/2000 | WO2000040235A2 Treatment of asthma with mek inhibitors |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000027363B1 Aerosols comprising nanoparticle drugs |
| 07/13/2000 | WO2000024897B1 Cell surface molecule-induced macrophage activation |
| 07/13/2000 | WO2000024741A3 Dihydropyridine compounds and their use as potassium channel openers |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 07/13/2000 | WO2000021487A3 Formoterol polymorphs |
| 07/13/2000 | WO2000009734A9 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 07/13/2000 | CA2753331A1 Soluble receptor br43x2 and methods of using |
| 07/13/2000 | CA2358939A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2358851A1 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356919A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | CA2356053A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
| 07/13/2000 | CA2350234A1 Treatment of asthma with mek inhibitors |
| 07/12/2000 | EP1018557A2 Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
| 07/12/2000 | EP1018517A2 Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases |
| 07/12/2000 | EP1018512A1 Novel basic derivatives of benz(e)isoindol-1-ones and pyrrolo(3,4-c)quinolin-1-ones with 5-HT3-antagonistic activity, their preparation and their therapeutic use |
| 07/12/2000 | EP1018506A1 Substituted alkyltetramine derivatives |
| 07/12/2000 | EP1017822A1 $i(LKTA) DELETION MUTANT OF $i(P. HAEMOLYTICA) |
| 07/12/2000 | EP1017723A2 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 07/12/2000 | EP1017713A1 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS |
| 07/12/2000 | EP1017711A2 Monocyclic compounds with four bifunctional residues having nk-2 antagonist action |
| 07/12/2000 | EP1017685A1 New 2-(3h)-oxazolone derivatives |
| 07/12/2000 | EP1017676A1 Method for the synthesis of quinoline derivatives |
| 07/12/2000 | EP1017673A1 Specific immunophilin ligands useful as anti-asthmatic, anti-allergic, anti-rheumatic, immunosuppressive, antipsoriatic and neuroprotective agents |
| 07/12/2000 | EP1017664A1 C3a receptor ligands |
| 07/12/2000 | EP1017440A1 Method of delivering halotherapy |
| 07/12/2000 | EP1017416A1 Treatment of cardiomyopathy |
| 07/12/2000 | EP1017398A1 Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| 07/12/2000 | EP1017385A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 |